4.7 Article

Quantifying the heritability of glioma using genome-wide complex trait analysis

Journal

SCIENTIFIC REPORTS
Volume 5, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/srep17267

Keywords

-

Funding

  1. Cancer Research UK - Bobby Moore Fund [C1298/A8362]
  2. Wellcome Trust
  3. DJ Fielding Medical Research Trust
  4. PhD studentship - Sir John Fisher Foundation
  5. NIH grants 5R01 [CA119215, 5R01 CA070917]
  6. American Brain Tumor Association
  7. National Brain Tumor Society
  8. Ligue Nationale contre le Cancer
  9. fondation ARC
  10. Institut National du Cancer (INCa) [PL046]
  11. French Ministry of Higher Education and Research
  12. program Investissements d'avenir [ANR-10-IAIHU-06]
  13. Genome Quebec, le Ministere de l'Enseignement superieur, de la Recherche, de la Science et de la Technologie (MESRST) Quebec
  14. McGill University
  15. Deutsche Forschungsgemeinschaft [Si552, Schr285]
  16. Deutsche Krebshilfe [70-2385-Wi2, 70-3163-Wi3, 10-6262]
  17. BONFOR
  18. German Federal Ministry of Education and Research (BMBF)
  19. Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg
  20. German National Genome Research Network (NGFN)
  21. Munich Center of Health Sciences (MC Health) as part of LMUinnovativ

Ask authors/readers for more resources

Genome-wide association studies (GWAS) have successfully identified a number of common single-nucleotide polymorphisms (SNPs) influencing glioma risk. While these SNPs only explain a small proportion of the genetic risk it is unclear how much is left to be detected by other, yet to be identified, common SNPs. Therefore, we applied Genome-Wide Complex Trait Analysis (GCTA) to three GWAS datasets totalling 3,373 cases and 4,571 controls and performed a meta-analysis to estimate the heritability of glioma. Our results identify heritability estimates of 25% (95% CI: 20-31%, P = 1.15 x 10(-17)) for all forms of glioma -26% (95% CI: 17-35%, P = 1.05 x 10(-8)) for glioblastoma multiforme (GBM) and 25% (95% CI: 17-32%, P = 1.26 x 10(-10)) for non-GBM tumors. This is a substantial increase from the genetic variance identified by the currently identified GWAS risk loci (similar to 6% of common heritability), indicating that most of the heritable risk attributable to common genetic variants remains to be identified.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available